This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amgen Highlights Data To Be Presented At 2013 European Cancer Congress

THOUSAND OAKS, Calif., Sept. 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present new data from studies of marketed and pipeline products at the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress happening Sept. 27 to Oct. 1 in Amsterdam.

"Amgen's continued focus on growth through innovation is highlighted by the data that we are presenting at the European Cancer Congress this year," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We are successfully advancing our pipeline, while using cutting-edge science to better understand each cancer's unique fingerprint and provide individualized care for patients."

Abstracts are available on the European Cancer Congress website at

Data presented on talimogene laherparepvec will include:

  • Secondary Endpoints from OPTiM: A Multicenter, Randomized Phase 3 Trial of Talimogene Laherparepvec vs. GM-CSF for the Treatment of Unresected Stage IIIB/C and IV MelanomaAbstract 3733 / P479, Poster Session, Monday, Sept. 30, 9:30 a.m. - 12:00 p.m. CEST (Hall 4)

Data presented on trebananib will include:

  • A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus the Angiopoietin 1 and 2 Inhibitor, Trebananib, or Placebo in Women With Recurrent Ovarian Cancer: TRINOVA-1Abstract 41, Late Breaking Abstract, Proffered Papers Session, Tuesday, Oct. 1, 10:53 - 11:05 a.m. CEST (Hall 7.2)

Data presented on Vectibix ® (panitumumab) will include:
  • ASPECCT: A Randomized, Multicenter, Open-Label, Phase 3 Study of Panitumumab vs. Cetuximab for Previously Treated Wild-Type KRAS Metastatic Colorectal CancerAbstract 18, Late Breaking Abstract, Proffered Papers Session, Saturday, Sept. 28, 1:47 - 2:10 p.m. CEST (RAI Auditorium)
  • Tumor Genetic Analysis of PRIME: KRAS, NRAS, and BRAF Mutations as Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving First-Line Treatment With Panitumumab Plus FOLFOX4Abstract 2275 / P157, Poster Session, Sunday, Sept. 29, 2:00 - 4:30 p.m. CEST (Hall 4)
  • Updated Overall Survival Analysis of Novel Predictive KRAS/NRAS Mutations Beyond KRAS Exon 2 in PEAK: A First-Line Phase 2 Study of FOLFOX6 plus Panitumumab or Bevacizumab in Metastatic Colorectal CancerAbstract 2262 / P144, Poster Session, Sunday, Sept. 29, 2:00 - 4:30 p.m. CEST (Hall 4)

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs